CytoDyn Inc. announced it has executed an exclusive supply and distribution agreement with Biomm S.A. in Brazil. This commercial agreement will enable Biomm to sell leronlimab in Brazil following regulatory clearance. CytoDyn has committed to conduct clinical trials in Brazil for all current indications for leronlimab (i.e., Long-Hauler COVID-19, NASH and cancer).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1578 USD | -28.97% | -34.00% | -19.08% |
May. 30 | Transcript : CytoDyn Inc. - Special Call | |
Apr. 15 | CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-19.08% | 157M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CYDY Stock
- News CytoDyn Inc.
- CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications